In most cases, acute cough is self-restrained, but its perseverance can be exasperating and can worsen the quality of life and common social participation [ 3]. Macfarlane J, Holmes W, Gard P, Macfarlane R, Rose D, Weston V, et al. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax. 2001;56(2):109–14. Tell your doctor or pharmacist if any of the above side-effects becomes serious or if you notice any other side-effects not listed above Reporting of side-effects Gastro-intestinal complaints such as stomach pain, heartburn, nausea or diarrhoea. Rare side-effects (affecting more than 1 in 10,000 but fewer than 1 in 1000 people) In the patient information leaflet, the patient is advised to consult a doctor immediately if his or her condition does not improve within one week, in case of fever lasting for several days or in case of shortness of breath or blood in the sputum.

Do not dispose of medicines in waste water or household waste. Ask your pharmacist how to dispose of the medicine when you stop using it. In doing so, they contribute to the protection of the environment. Special notes on the content Tests on reproductive toxicity, genotoxicity and carcinogenicity have not been performed. 6 Pharmaceutical particulars 6.1 List of excipients Of 543 patients screened, 261 were eligible, of whom 134 (51%) were recruited and 103 (77%) returned a completed diary. Overall, 41% (41/100) of patients took antibiotics (Kaloba® liquid group: 48% [15/31]; placebo liquid group: 23% [6/26]; Kaloba® tablet group: 48% [9/21]; placebo tablet group: 50% [11/22]). Most patients adhered to the study medication (median 19 out of 21 doses taken in week 1, IQR 18–21 - all arms combined). There were no serious adverse events relating to treatment. Most patients interviewed found study recruitment to be straightforward, but some found the diary too complex. Conclusions Familiarization: repeated readings of transcripts and listening to recordings assisted familiarisation with the data, identification of initial codes and interesting pieces of dataThe extract (EPs® 7630) used in the herbal medicinal product (Kaloba® manufactured by Dr. Willmar Schwabe GmbH & Co. KG, Germany) is classified by the European Pharmacopoeia as “other extract” and therefore not adjusted to a particular content of constituents. Independent of this formal classification, the constituents of this herbal active ingredient have been described in detail [ 36]. Approximately 80% m/m of the extract are assigned to six major groups of constituents, oligomeric prodelphinidines (commonly designated in this context as polyphenols) being the most significant group (approximately 40% of the dried extract). We conducted a phase II double-blind feasibility trial with UK GP practices cluster-randomised to give liquid or tablet preparation (for logistical reasons), and within each practice, eligible patients were individually randomised to Pelargonium sidoides root extract (EPs®7630 – Kaloba®) or matched placebo. The detailed protocol for this trial has already been published [ 33]. This trial adheres to CONSORT guidelines. Participants if you are allergic (hypersensitive) to pelargonium or any of the other ingredients listed in section 6.

In addition to the trial treatment, GPs were allowed to select the clinically appropriate prescribing strategy as per practice policy, no antibiotics or to prescribe antibiotics, either to be taken immediately, or as a “delayed” prescription. Outcomes Signs indicating changes in liver function have been reported after taking Kaloba;however, the causal relationship between these effects and the use of the product has not been demonstrated. After taking this product A. Fever, diarrhoea, restlessness, dark coloured urine, fatigue and stomach disturbances are some common side effects. However, due to insufficient research, some individuals like pregnant mothers, lactating mothers and even children should refrain from its consumption. Q. How can you use geranium oil? If you have any questions, or are unsure about anything, please ask your doctor, pharmacist or healthcare practitioner. Side-effects Syrup: Xylitol, glycerol 85%, citric acid anhydrous, potassium sorbate, xanthan gum, purified water.Kayser O, Kolodziej H, Kiderlen AF. Immunomodulatory principles of Pelargonium sidoides. Phytotherapy research: PTR. 2001;15(2):122–6. Tablet core: Maltodextrin, microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, precipitated silica, magnesium stearate.

Although there are no data on cases of overdose, overdose is likely to increase side-effects. Thus, treatment should be symptomatic and as clinically indicated. 5. Pharmacological properties 5.1 Pharmacodynamic properties

6. Pharmaceutical particulars

Kaloba has no or negligible influence on the ability to drive and use machines. 4.8 Undesirable effects In recent years, the inappropriate prescription of antitussive pharmacological treatments in children has decreased; however, paediatricians’ prescriptions currently do not always reflect an accurate treatment of cough [ 3]. According to epidemiological data, cough occurring in children produces more anxiety than in cough occurring in adults, and many people view this symptom as “a disease”. A recent Italian survey confirms this view, suggesting that some inclinations of paediatricians’ therapeutic practice should be modified to achieve better control of cough in children and to reduce its impact [ 3]. Moreover, when attempting to treat cough, children are administered over-the-counter products with little or no scientific evidence of proven efficacy [ 6]. In single cases, signs indicating disturbances of liver function have been reported after intake of Kaloba; the causal relationship between this effect and the application of the product has not been demonstrated. 4.9 Overdose